Nkarta, Inc. (NASDAQ:NKTX) Shares Purchased by Tang Capital Management LLC

Tang Capital Management LLC grew its holdings in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 252.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,293,719 shares of the company's stock after acquiring an additional 1,643,719 shares during the period. Tang Capital Management LLC owned 3.25% of Nkarta worth $5,711,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of NKTX. Invesco Ltd. bought a new position in Nkarta in the 4th quarter worth approximately $30,000. Sequoia Financial Advisors LLC purchased a new stake in Nkarta during the fourth quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Nkarta during the 4th quarter valued at $37,000. ProShare Advisors LLC bought a new stake in shares of Nkarta in the 4th quarter worth about $45,000. Finally, Catalina Capital Group LLC boosted its position in shares of Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock valued at $47,000 after buying an additional 6,867 shares during the period. 80.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Stifel Nicolaus cut their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 27th. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. William Blair reissued a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. Finally, Needham & Company LLC cut their price target on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $14.67.

Nkarta Trading Down 1.7%

NKTX traded down $0.03 during midday trading on Friday, hitting $1.74. 110,059 shares of the company were exchanged, compared to its average volume of 1,206,781. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23. The firm has a market capitalization of $123.11 million, a price-to-earnings ratio of -0.92 and a beta of 0.81. The company's 50 day simple moving average is $1.79 and its 200 day simple moving average is $2.16.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. On average, equities analysts anticipate that Nkarta, Inc. will post -1.7 EPS for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.